Hepatx Corporation

Hepatx is developing innovative regenerative medicine solutions for serious liver disease.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Palo Alto, CA, USA
  • Currency USD
  • Founded November 2015
  • Employees 2
  • Incorporation Type C-corp
  • Website hepatx.com

Company Summary

We are developing cell therapies to address the $5 billion+ market for life-threatening liver diseases. The technology was invented at Stanford and improved by Hepatx. We use adult stem cells to scalably make hepatocyte-like cells to treat liver failure. Our first product candidate, Hx-001, will target hepatitis. It is not limited by supply and costs less than transplant. Future plans include development for other chronic diseases.

Team

  • Eric Schuur
    CEO

    Biotech leader: led Calydon's product from concept to clinic (acquired by CellGenesys) & Asthmatx's clinical study design/analysis resulting in PMA approval (acquired by Boston Scientific). Consulted for molecular diagnostics development (Genomic Health, Janssen, J&J). Stanford mentor (OTL iFarm, SPARK). Ph.D. Experimental Pathology, UCLA.

  • Claudia Preziosi
    Head of Business Development and Operations

    Experienced operations & program manager with a proven track record of success at StartX (700+ startups, 16 Unicorns). Managed a 9-market portfolio for Nestlé Waters (IBU San Pellegrino). Founder of Preziosi Consultancy. Stanford-trained project manager.

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free